| For: | Yu J, Lv YM, Yang P, Jiang YZ, Qin XR, Wang XY. Safety and effectiveness of vonoprazan-based rescue therapy for Helicobacter pylori infection. World J Gastroenterol 2023; 29(20): 3133-3144 [PMID: 37346155 DOI: 10.3748/wjg.v29.i20.3133] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v29/i20/3133.htm |
| Number | Citing Articles |
| 1 |
Valerie Josephine Dirjayanto, Jessica Audrey, Daniel Martin Simadibrata. Vonoprazan-amoxicillin dual regimen with <i>Saccharomyces boulardii</i> as a rescue therapy for <i>Helicobacter pylori</i>: Current perspectives and implications. World Journal of Gastroenterology 2024; 30(10): 1280-1286 doi: 10.3748/wjg.v30.i10.1280
Abstract(830) |
Core Tip(970) |
Full Article(HTML)(4487)
|
Full Article (PDF)-570K(267)
|
Full Article with Cover (PDF)-823K(219)
|
Full Article (Word)-173K(3)
|
Full Article (XML)-94K(139)
|
Audio-1404K(15)
|
Peer-Review Report-216K(138)
|
Answering Reviewers-96K(148)
|
Times Cited (2)
|
Total Visits (5744)
|
Open
|
| 2 |
Yu Huang, Jin-Nan Chen, Shu-Han Qiu, Yi-Xian Guo, Mei-Xuan Li, Ya-Nan Gao, Xiao Liang, Yue-Hua Han, Ping Xu, Jing Wang, Hong Lu. Vonoprazan-amoxicillin dual, rifabutin-based triple, and bismuth quadruple therapies for Helicobacter pylori rescue treatment: a multicentre, open-label, non-inferiority randomised trial. The Lancet Regional Health - Western Pacific 2026; 68 doi: 10.1016/j.lanwpc.2026.101815
|
| 3 |
Stanislav I. Sitkin. <i>Limosilactobacillus reuteri</i> DSM 17648 as an adjuvant in the fight against <i>Helicobacter pylori</i> infection: Mechanisms of action, clinical efficacy, and prospects. Almanac of Clinical Medicine 2026; doi: 10.18786/2072-0505-2026-54-001
|
| 4 |
Lazzat Zhussupbekova, Alina Bulatova, Dinara Nurkina, Klara Kurmangaliyeva, Venera Rakhmetova, Aigyul Izhanova, Kaergeldy Makhambetov, Elmira Akhmedyarova. Therapeutic Potential of Probiotics in the Modulation of Antibiotic Resistance in Helicobacter pylori. Biomedicines 2026; 14(5) doi: 10.3390/biomedicines14051044
|
| 5 |
Ding-Ni Qu, Ze-Xuan Ji, Jun-Qi Zhang, Xiao-Yong Wang. Vonoprazan–Amoxicillin Dual Therapy with or Without Saccharomyces boulardii Supplementation as a Rescue Regimen for Helicobacter pylori Infection. Infection and Drug Resistance 2026; doi: 10.2147/IDR.S594118
|
| 6 |
Qingsong Qu, Wanhong Zhu, Xingjian Song, Jingqi Zeng, Jie Lin, Xia Ding. From Eradication to Holistic Regeneration: Pharmaceutics Strategies for Reshaping Gastric Homeostasis Against H. pylori Infection. Pharmaceutics 2026; 18(3) doi: 10.3390/pharmaceutics18030337
|
| 7 |
Jie Zhang, Xin Cao, Kai Ma, Yizhou Jiang, Xiangrong Qin, Xiaoyong Wang. Safety and effectiveness of dual therapy for Helicobacter pylori infection and the effect on the glycated hemoglobin level in type 2 diabetes. Scientific Reports 2025; 15(1) doi: 10.1038/s41598-025-85628-5
|
| 8 |
Ju Zhang, Xinzhao Wang, Shujie Song, Xiaoming Zhu, Ting Lv, Lingling Wang, Lei Lei, Yuhui Wang, Yali Lei, Yating Wang, Xiaojing Zhu, Lifeng Zhang, Min Chen, Yongquan Shi. Efficacy and Safety of Vonoprazan and High‐Dose Amoxicillin Dual Therapy for Rescue Treatment of Helicobacter pylori Infection: A Multicenter Randomized Controlled Trial. United European Gastroenterology Journal 2025; 13(8) doi: 10.1002/ueg2.70070
|
| 9 |
Weiwei Wang, Lei Wang, Qingqing Fan, Jingyan Xu, Yifan Li, Jiale Xu, Bei Zhao, Dan Ge, Longying Xiong, Yanping Wu, Yun Zhu, Min Chen. Macrophage Membrane-Coated Liposomes Delivering Vonoprazan Disrupt Mitochondrial Oxidative Phosphorylation in Diffuse Large B-Cell Lymphoma. International Journal of Nanomedicine 2025; doi: 10.2147/IJN.S520567
|
| 10 |
Karolina Kornatowska, Edyta Hańczyk, Dawid Piecuch, Szymon Kopciał, Natalia Pawelec, Weronika Mazur, Mateusz Tyniec, Kamal Morshed. A Novel Approach to H. pylori Eradication: A Narrative Review of Vonoprazan-Based Therapies. Gastroenterology Insights 2025; 16(3) doi: 10.3390/gastroent16030035
|